Cite

HARVARD Citation

    Li, J. et al. (2017). Real-world cost–effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of China. Journal of comparative effectiveness research. pp. 205-218. [Online]. 
  
Back to record